To Top

Community

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

Contribution
Acquisition

Novacap acquires interest in Mailhot Industries

PR-M02-18-NI-80
Drug Development

Evotec and MaRS Innovation Announce First Funded Project under LAB150 Bridge

PR-M02-18-NI-79
Antibiotic-Resistant

ABAC Therapeutics Announces €16 Million Series A to Develop Therapeutic Solutions to Fight Antibiotic-Resistant Bacteria

PR-M02-18-NI-78
FDA Approval

FDA approves new treatment for a certain type of prostate cancer using novel clinical trial endpoint

PR-M02-18-NI-77
Orphan Drug

Selumetinib Granted Orphan Drug Designation by the U.S. FDA for Neurofibromatosis Type 1

PR-M02-18-NI-76
Appointment

Marken Appoints New Vice President, Global Quality Assurance

PR-M02-18-NI-81
FDA

Ortho Dermatologics Announces U.S. FDA Filing Acceptance For JEMDEL™ Plaque Psoriasis Treatment

PR-M02-18-NI-75
Clinical Trials

Mallinckrodt Enrolls First Patient in Phase 1 Study of ExpressGraft™C9T1 Skin Tissue

PR-M02-18-NI-74
Breakthrough Therapy

Pfizer Receives Breakthrough Therapy Designation from FDA for PF-04965842

PR-M02-18-NI-72
Strategic Collaboration

Bristol-Myers Squibb and Nektar Therapeutics Announce Global Development & Commercialization Collaboration for Nektar’s CD122-biased Agonist, NKTR-214

PR-M02-18-NI-73
Approval

Celltrion Receives EU Approval for Trastuzumab Biosimilar

PR-M02-18-NI-71
Acquisition

Mallinckrodt Completes Acquisition Of Sucampo Pharmaceuticals, Inc.

PR-M02-18-NI-62
Cell Culture Portfolio

Lonza Expands Cell-Culture Portfolio with Quasi Vivo ® System

PR-M02-18-NI-59
OEM

BioLife Solutions Executes OEM Agreement with MilliporeSigma

Appointment

Charles River Laboratories Announces Executive Management Appointments

PR-M02-18-NI-58
SCRS' Global Impact Partner Program

Boehringer Ingelheim Demonstrates their Commitment to Site Relationships by Joining SCRS' Global Impact Partner Program

PR-M02-18-NI-56
Dermatology

Sun Pharma Announces Twelve Tildrakizumab Abstracts to be Presented at American Academy of Dermatology 2018 Annual Meeting

PR-M02-18-NI-54
Strategic Collaboration

Sirenas Enters Into Multi-Target Collaboration With Bristol-Myers Squibb

PR-M02-18-NI-55
Inhalation

Teva Announces U.S. Launch of QVAR® RediHaler™ (Beclomethasone Dipropionate HFA) Inhalation Aerosol

PR-M02-18-NI-53
Priority Review

U.S., EU and Japan Health Authorities Accept Regulatory Submissions for Review of Pfizer’s Third-Generation ALK Inhibitor Lorlatinib

PR-M02-18-NI-52
Strategic Partnership

ImmunoQure AG and Servier Enter into Strategic Partnership for the Development of an Interferon-alpha Human Autoantibody

PR-M02-18-NI-64
Generics

Teva Announces Launch of a Generic Version of Syprine® in the United States

PR-M02-18-NI-050
Drug Development

WuXi Biologics Congratulates Tychan for Dosing First Patient of a Zika Antibody after Record 9 Months of Development

PR-M02-18-NI-049
FDA Approval

Pii and Its Partners Received FDA Market Approval for Seven Products and Commercially Launched 6 Products in 2017

PR-M02-18-NI-048
Strategic Partnership

Denali Therapeutics and Lonza Pharma & Biotech Announce Exclusive Partnership to Develop and Produce Biologic Medicines

PR-M02-18-NI-047
Acquistion

Charles River Laboratories to Acquire MPI Research

PR-M02-18-NI-57
FDA Approval

Novartis receives FDA approval for Cosentyx® label update to include moderate to severe scalp psoriasis

PR-M02-18-NI-046
Drug Development

AbbVie receives a positive recommendation from the CADTH Canadian Drug Expert Committee for MAVIRET™

PR-M02-18-NI-044
Launch

WuXi AppTec Launches Advanced Library Compound Initiative on LabNetwork.com

PR-M02-18-NI-039
Award

Thermo Fisher Scientific Wins CiteAb 2018 Award for its Antibody Validation Initiative

PR-M02-18-NI-040
Animal Health

Merial, Now Part of Boehringer Ingelheim, Grows Canine Vaccine Portfolio With Introduction of RECOMBITEK® Oral Bordetella

PR-M02-18-NI-038
Strategic Partnership

AbbVie and MBC BioLabs Team Up to Support Life-Science Startups in the San Francisco Bay Area

PR-M02-18-NI-037
Packaging

SCHOTT AG, ARaymondlife and Vanrx Pharmasystems announce product compatibility for primary packaging of sterile injectables

PR-M02-18-NI-035
Marketing

Evonik Launches a New MetAMINO® Marketing Campaign to the Middle East and African Markets At VIV MEA in Abu Dhabi

PR-M02-18-NI-033
Launch

Thermo Fisher Scientific Launches Axiom Microbiome Array for Research

PR-M02-18-NI-032
CDMO

Grünenthal Group Receives FDA's Expedited Access Pathway Designation for VIVO

PR-M02-18-NI-030
Certification

Merck KGaA, Darmstadt, Germany certified as one of the Top Employers North America 2018

PR-M02-18-NI-028
Acquistion

Celgene Corporation Commences Tender Offer for Juno Therapeutics, Inc.

PR-M02-18-NI-026
Generic

Mylan Expands Access to HIV/AIDS Medicines with Launch of First Generic Sustiva® Tablets

PR-M02-18-NI-025
Appointment

PPD Names Maria Teresa Hilado, CFO of Allergan, to its Board of Directors

PR-M02-18-NI-023
Joint Venture

DSM and Evonik Establish Veramaris Joint Venture

PR-M02-18-NI-024
Innovation

Thermo Fisher Scientific Receives Manufacturing Leaders' Innovation Award

PR-M02-18-NI-023
Acquistion

Partner Therapeutics (PTx) Acquires Leukine® from Sanofi

PR-M02-18-NI-021
Market Expansion

Marken Accelerates Its Reach And Growth In Clinical Trial Logistics

PR-M02-18-NI-031
Immuno-Oncology

Syndax Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca

PR-M02-18-NI-020
CEO

Rentschler Biopharma SE Appoints International Biopharma Expert Dr. Ralf Otto as Chief Operating Officer

PR-M02-18-NI-018
Investment

Charles River Laboratories Makes Investments in High-Throughput Screening Infrastructure

PR-M02-18-NI-017
Leadership

Avara Pharmaceutical Services Wins CMO Leadership Awards in All 6 Categories for Contract Manufacturing

PR-M02-18-NI-016
Financing

Engine Biosciences Raises $10 Million in Seed Financing to Accelerate Drug Discovery Using Genomics and Artificial Intelligence

PR-M02-18-NI-015
Expanded Capacity

Cambrex Expands Process Research and Development Capabilities Across North America

PR-M02-18-NI-014
Contract

Prime Therapeutics and Boehringer Ingelheim Enter Into Outcomes-Based Contract for Jardiance®

PR-M02-18-NI-013
Staffing

Boehringer Ingelheim Announces Paul Fonteyne to Retire at the end of 2018

PR-M02-18-NI-012
IND Application

WuXi Biologics Congratulates BioAtla on FDA Clearance of IND Application for CAB-AXL-ADC

PR-M02-18-NI-011
Oncology

Stand Up To Cancer Announces $11M Collaborative, Multi-Disciplinary Research Program

PR-M02-18-NI-010
Partnership

Agilent Partners with Science Exchange

PR-M02-18-NI-009
Discovery

Scientists Discover How Gene Mutation Triggers Immune Disease

PR-M02-18-NI-008
Strategic Collaboration

WuXi Biologics and Aravive Biologics to Form Strategic Manufacturing Collaboration Following Successful IND Filing for AVB-S6-500

PR-M02-18-NI-007
Agreement

BioDuro Announces Cooperation Agreement with Porton Pharma Solutions

PR-M02-18-NI-006
New Drug Application

Theravance Biopharma and Mylan Announce FDA Acceptance of New Drug Application for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease

PR-M02-18-NI-005
Distribution

Nexeo Solutions Announces New Distribution Agreement in Mexico for BASF Personal Care

PR-M02-18-NI-004
Vaccine

Takeda’s Zika Vaccine Candidate Receives U.S. FDA Fast Track Designation

PR-M02-18-NI-003
Laboratory

New, Automated UV-Visible Spectrophotometers are Designed for Today's Modern Lab

PR-M02-18-NI-002
Acquisition

CASI Pharmaceuticals Acquires ANDA Portfolio From Sandoz Inc. (Sandoz)

PR-M02-18-NI-001
Forecast

Biotechnology Companies Prepared for a Big 2018

PR-M01-18-NI-099
Oncology

Specific Protein Plays Key Role in the Spread of Breast Cancer

PR-M01-18-NI-098
Drug Development

New Real-World Analysis Finds Lower Risk of Major Bleeding and Similar Risk of Stroke with Standard Dose of Pradaxa® Compared to Rivaroxaban

PR-M01-18-NI-097
Acquistion

Novacap TMT Enters into Definitive Agreement to Acquire Horizon Telcom

PR-M01-18-NI-096
Drug Development

Janssen to Present 14 Abstracts in Prostate and Urothelial Cancers at ASCO GU 2018

PR-M01-18-NI-095
Wearable Devices

Wearable Medical Devices Market 18.3% CAGR to 2022

PR-M01-18-NI-094
Market Insight

Global Stroke Management Market Expected to Reach $36,756 million by 2023 — Allied Market Research

PR-M01-18-NI-092
Healthcare

Innovation in Telemedicine and mHealth Solutions Significantly Changing the Healthcare Industry

PR-M01-18-NI-091
Efficacy

Efficacy Testing Market Worth 501.6 Million USD by 2022

PR-M01-18-NI-090
Strategic Partnership

Biocartis & Immunexpress Sign Partnership for a Sepsis Host Immune Response Test on the Idylla™ platform

PR-M01-18-NI-094
Market Prediction

Focal Segmental Glomerulosclerosis Market to Reach US$15.83 Billion by 2025, Globally: Transparency Market Research

PR-M01-18-NI-093
Point-of-care

Point-of-care Diagnostics Market is Estimated to Register a CAGR of 6.9% by 2024, Globally: Transparency Market Research

PR-M01-18-NI-091
Licensing

Grace Licenses UNIPOL® PP Process Technology to Grupa Azoty in Poland

PR-M01-18-NI-090
Appointment

UPM Pharmaceuticals appoints Daniel Dixon as Vice President of Quality Control

PR-M01-18-NI-088
Capacity Expansion

Paragon Bioservices Announces New Commercial Manufacturing Facility Expansion

PR-M01-18-NI-087
Biosimilars

Sandoz - Biocon Deal One More Sign That U.S. Biosimilars Have Arrived

PR-M01-18-NI-086
Drug Discovery

X-Chem Enters Expanded Global Drug Discovery and Technology Transfer Collaboration with AstraZeneca

PR-M01-18-NI-073
Immuno-Oncology

European Commission Approves Bristol-Myers Squibb’s Yervoy (ipilimumab) for Treatment of Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma

PR-M01-18-NI-082
Oncology

Combination of Encorafenib, Binimetinib and Cetuximab Demonstrated an 8 Month Median Progression-Free Survival

PR-M01-18-NI-081
Approval

LYNPARZA® (olaparib) Receives Approval in Japan for the Treatment of Advanced Ovarian Cancer

PR-M01-18-NI-078
Inhalation

Hovione strengthens Inhalation Services portfolio

PR-M01-18-NI-084
Biosimilar

European Commission Approves Amgen And Allergan's MVASI® (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer

PR-M01-18-NI-077
Opening

Marken Opens New Location In Stuttgart, Germany

PR-M01-18-NI-083
Opadry System

Colorcon, Inc. Transforms the Sugar Coating Process with a New Opadry System

PR-M01-18-NI-071
Strategic Collaboration

NeuroMetrix and GlaxoSmithKline Consumer Healthcare Announce Strategic Collaboration to Develop and Expand Access to Quell Wearable Pain Relief Technology

PR-M01-18-NI-075
Oncology

Overall Survival Analysis From KYPROLIS® (Carfilzomib) Phase 3 ASPIRE Trial Published in the Journal of Clinical Oncology

PR-M01-18-NI-074
Appointment

UPM Pharmaceuticals appoints Chris Curtin as Chief Operating Officer

PR-M01-18-NI-076
Clinical Trials

Celerion Creates a Fully Automated, Early Development Clinical Trial Data Management Platform

PR-M01-18-NI-070
Medical Device

AMRI Experts to Lead Discussion on Bringing a Medical Device to Market at MD&M West 2018

PR-M01-18-NI-069
Launch

Roche launches CE-marked VENTANA MMR IHC Panel for patients diagnosed with colorectal cancer

PR-M01-18-NI-068
Technology

Thermo Fisher Scientific Announces More Than 30 Orders for Ion GeneStudio S5 One Week After Debut

PR-M01-18-NI-067
FDA Approval

FDA approves new indication for Gilotrif® in EGFR mutation-positive NSCLC

PR-M01-18-NI-062
Research

Lustgarten Foundation Awarded $22 Million For Pancreatic Cancer Research

PR-M01-18-NI-066
Appointment

Charles River Laboratories Adds Jean-Paul Mangeolle to Board of Directors

Oncology

Merck's KEYTRUDA(R) (pembrolizumab) Significantly Improved Overall Survival and Progression-Free Survival as First-Line Treatment

PR-M01-18-NI-063
Ceremony

Cambrex & AstraZeneca Hold Ceremony to Mark Long-Term Supply Agreement at Karlskoga, Sweden Facility

PR-M01-18-NI-062
Regulatory

Sandoz regulatory submission for proposed biosimilar adalimumab accepted by FDA

PR-M01-18-NI-060
Launch

DSM Sinochem Pharmaceuticals successfully launches Rosuvastatin finished dosage formulation in Western Europe

PR-M01-18-NI-054
Appointment

Cytovance® Biologics Welcomes Edwin Miranda as Vice President of Quality

PR-M01-18-NI-061
Partnership

Servier Canada and the New Brunswick Health Research Foundation announce the creation of the Servier-New Brunswick Cardiac Health Improvement Fund (CHIF)

PR-M01-18-NI-058
Expanded Capacity

Marken Opens New Kit Building Facility In Shanghai

PR-M01-18-NI-057
Oncology

Olympus PeriView FLEX TBNA Needle Brings New Capabilities to Early Diagnosis of Lung Disease

PR-M01-18-NI-056
Rights Acquisition

Nuvo Pharmaceuticals (Ireland) Limited Acquires U.S. Product Rights to Resultz® from Piedmont Pharmaceuticals LLC

PR-M01-18-NI-055
FDA Approval

Teva Announces U.S. FDA Approval of TRISENOX® (arsenic trioxide) Injection for First Line Treatment of Acute Promyelocytic Leukemia

PR-M01-18-NI-053
Animal Nutrition

Evonik and Fufeng Group Enter Strategic Partnership for the Production of TherAMINO®

PR-M01-18-NI-049
FDA Approval

U.S. FDA Approves LYNPARZA® (olaparib) in Germline BRCA-Mutated Metastatic Breast Cancer

PR-M01-18-NI-052
Acquisition

Croda Buys Tech Companies in Canada, Finland

PR-M01-18-NI-048
Appointment

WuXi Biologics Appoints Dr. Chiang Syin, a Former FDA Officer as Chief Quality Officer

PR-M01-18-NI-050
FDA

FDA Approves First Treatment for Breast Cancer with a Certain Inherited Genetic Mutation

PR-M01-18-NI-047
Vaccine

GSK receives FDA approval for expanded indication for FLUARIX® QUADRIVALENT (Influenza Vaccine) for persons 6 months and older

PR-M01-18-NI-046
Cardiovascular

Secant Group Develops the First Synthetic Regenerative Cardiovascular Graft

PR-M01-18-NI-052
Drug Development

PharmaFluidics Raises 7.3 Million Euro to Expand Commercialization of Novel Micro-Chip Device for Biomarker, Diagnostics and Drug Development Applications

PR-M01-18-NI-044
Immuno-Oncology

Forty Seven Inc. to Collaborate with Merck KGaA, Darmstadt, Germany, on a Novel Immuno-Oncology Combination for Ovarian Cancer

PR-M01-18-NI-042
//Fix for text overflow in cards